PRP in Osteoarthritis (OA) Knee: Correct Dose Critical for Long Term Clinical Efficacy
Bansal H · Scientific Reports (Nature) (2021)
DOI: 10.1038/s41598-021-83025-2This RCT compared high-dose PRP (10 billion platelets per injection) versus HA in 150 patients with knee OA. The study is notable for its precise platelet quantification and for including MRI structural outcomes. The PRP group showed significantly better WOMAC and VAS scores at 12 months and, uniquely, demonstrated MRI evidence of structural cartilage improvement, which is rarely reported in PRP trials.
Clinical Relevance
A pivotal study demonstrating that high-dose PRP not only improves symptoms but may modify disease structure on MRI. The 10 billion platelet threshold provides a concrete dosing target for clinicians seeking to replicate these results.
Key Takeaways
- Used precisely quantified high-dose PRP (10 billion platelets per injection)
- PRP significantly superior to HA at 12 months (WOMAC, VAS)
- MRI showed structural cartilage improvement in PRP group (rare finding)
- Highlights the importance of absolute platelet dose, not just fold-concentration
- One of the strongest individual RCTs supporting high-dose PRP for knee OA
Key Findings
PRP (10 billion platelet dose) was significantly superior to HA across all outcomes at 12 months. MRI also showed structural improvement.
Clinical Context
Study Design
Randomized Controlled Trial
Condition
Knee Osteoarthritis
Sample Size
150 patients
Follow-up
12 months
Control Group
Hyaluronic Acid (4 mL)
Primary Outcome
WOMAC, IKDC, 6-Minute Walk Distance
PRP Protocol & Intervention
Preparation System
Manual (with novel filtration step)
Platelet Concentration
~90% platelet recovery, target dose 10 billion
Spin Protocol
Manual with added filtration step
Injection Frequency
1 injection(s)